ReCode Therapeutics raised undisclosed funding to develop lipid nanoparticle platforms for precise delivery of genetic therapies to specific organs and tissues, offering new options for patients with life-limiting rare diseases.
ReCode Therapeutics raised undisclosed funding to develop lipid nanoparticle platforms for precise delivery of genetic therapies to specific organs and tissues, offering new options for patients with life-limiting rare diseases.
